Resistance in gram-negative bacteria: Enterobacteriaceae

被引:299
作者
Paterson, David L. [1 ]
机构
[1] Univ Pittsburgh, Med Ctr, Antibiot Management Program, Pittsburgh, PA USA
关键词
antimicrobial resistance; community-acquired infections; Enterobacteriaceae; gram-negative bacteria; nosocomial infections;
D O I
10.1016/j.amjmed.2006.03.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The emergence and spread of resistance in Enterobacteriaceae are complicating the treatment of serious nosocomial infections and threatening to create species resistant to all currently available agents. Approximately 20% of Klebsiella pneumoniae infections and 31% of Enterobacter spp infections in intensive care units in the United States now involve strains not susceptible,to third-generation cephalosporins. Such resistance in K pneumonia to third-generation cephalosporins is, typically caused by the acquisition of plasmids containing genes that encode for extended-spectrum beta-lactamases (ESBLs), and these plasmids often carry other resistance genes as well. ESBL-producing K pneumoniae And Escherichia coli are now relatively common in healthcare settings and often exhibit multidrug resistance. ESBL-producing Enterobacteriaceae have now emerged in the community as well. Salmonella and other Enterobacteriacea. e that cause gastroenteritis may Also be ESBL producers, which is of relevance when children require treatment for invasive infections. Resistance of Enterobacter spp to third-generation cephalosporins is most typically caused by overproduction of AmpC beta-lactamases, and treatment with third-generation cephalosporins may select for AmpC-overproducing mutants. Some Enterobacter cloacae. strains are now ESBL and AmpC producers, conferring resistance to both third- and fourth-generation cephalosporins. Quinolone resistance in Enterobacteriaceae is usually the result of chromosomal mutations leading to alterations in target enzymes or drug accumulation. More recently, however, plasmid-mediated quinolone, resistance has been reported in K pneumoniae and E coli, associated with acquisition of the qnr gene. The vast majority of Enterobacteriaceae, including ESBL producers, remain susceptible to carbapenems, and these agents are considered preferred empiric therapy for serious Enterobacteriaceae infections. Carbapenem resistance, although rare, appears to be increasing. Particularly troublesome is the emergence of,KPC-type carbapenemases in New York City. Better antibiotic. stewardship and infection control are needed-to prevent further spread of ESBLs and other forms of resistance in Enterobacteriaceae throughout the, world. (c) 2006 by the Association for Professionals in Infection Control and Epidemiology, Inc. and Elsevier Inc. All tights reserved.
引用
收藏
页码:S20 / S28
页数:9
相关论文
共 83 条
[1]   Epidemiology of conjugative plasmid-mediated AmpC β-lactamases in the United States [J].
Alvarez, M ;
Tran, JH ;
Chow, N ;
Jacoby, GA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (02) :533-537
[2]   Imipenem resistance of Enterobacter aerogenes mediated by outer membrane permeability [J].
Bornet, C ;
Davin-Regli, A ;
Bosi, C ;
Pages, JM ;
Bollet, C .
JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (03) :1048-1052
[3]  
Bouza Emilio, 2002, Semin Respir Infect, V17, P215, DOI 10.1053/srin.2002.34693
[4]   Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 β-lactamases in New York City [J].
Bradford, PA ;
Bratu, S ;
Urban, C ;
Visalli, M ;
Mariano, N ;
Landman, D ;
Rahal, JJ ;
Brooks, S ;
Cebular, S ;
Quale, J .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (01) :55-60
[5]   Extended-spectrum β-lactamases in the 21st century:: Characterization, epidemiology, and detection of this important resistance threat [J].
Bradford, PA .
CLINICAL MICROBIOLOGY REVIEWS, 2001, 14 (04) :933-951
[6]   Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the loss of an outer membrane protein [J].
Bradford, PA ;
Urban, C ;
Mariano, N ;
Projan, SJ ;
Rahal, JJ ;
Bush, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (03) :563-569
[7]   Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY:: molecular epidemiology and in vitro activity of polymyxin B and other agents [J].
Bratu, S ;
Tolaney, P ;
Karumudi, U ;
Quale, J ;
Mooty, M ;
Nichani, S ;
Landman, D .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 56 (01) :128-132
[8]   Detection of KPC carbapenem-hydrolyzing enzymes in Enterobacter spp. from Brooklyn, New York [J].
Bratu, S ;
Landman, D ;
Alam, M ;
Tolentino, E ;
Quale, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (02) :776-778
[9]   Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City -: A new threat to our antibiotic armamentarium [J].
Bratu, S ;
Landman, D ;
Haag, R ;
Recco, R ;
Eramo, A ;
Alam, M ;
Quale, J .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (12) :1430-1435
[10]   Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York:: Epidemiology and recommendations for detection [J].
Bratu, S ;
Mooty, M ;
Nichani, S ;
Landman, D ;
Gullans, C ;
Pettinato, B ;
Karumudi, U ;
Tolaney, P ;
Quale, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (07) :3018-3020